In a report released yesterday, Yaron Werber from Cowen & Co. maintained a Buy rating on BeiGene Ltd (BGNE), with a price target of $170. The company’s shares opened today at $139.06.
According to TipRanks.com, Werber is ranked #383 out of 5203 analysts.
Currently, the analyst consensus on BeiGene Ltd is a Strong Buy with an average price target of $180.
See today’s analyst top recommended stocks >>
Based on BeiGene Ltd’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $143 million. In comparison, last year the company had a GAAP net loss of $99.79 million.
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BGNE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290).
